ALSO READSun Pharma recalls diabetes drug in US over microbial contamination Sun Pharmaceutical gets USFDA inspection report for Dadra facility No major respite for Sun Pharma Zydus gets US health regulator nod for hypertension drug Nifedipine Zydus Cadila gets USFDA approval for anti-depression drug
Sun Pharmaceutical Industries has started recalling two batches of Riomet (metformin hydrochloride) Oral Solution voluntarily from the US market due to microbial contamination. According to a notification put up by the US Food and Drug Administration in its website, the recall was initiated by the firm under 'Class-II' classification.
The notification did not mention the quantity that is being recalled. "The Riomet (Metformin Hydrochloride Oral Solution) has been found to be contaminated (with Scopulariopsis brevicaulis). The contamination was discovered during sample preparation for the Antimicrobial Preservative Effectiveness Testing (AMPET) being performed as part of the 12 month stability study interval," Sun Pharma informed the FDA in a letter. Riomet (metformin oral solution) is an oral diabetes medicine that helps control blood sugar level. According to the USA health regulator, Class II recall is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. The drug was manufactured for Ranbaxy Laboratories Inc Jacksonville in USA by a contract manufacturer and distributed by Sun Pharmaceutical Industries' subsidiary in Cranbury, New Jersey. The Sun Pharma stock closed at Rs 528.60 apiece on BSE, up 0.28 per cent over previous close.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)